Diabetes (Type 2)

The research is being done to test whether the active study drug, sotagliflozin, is safe in patients who have diabetes, kidney disease and who are at risk for cardiovascular events such as heart attack and stroke.

Anticipated date that enrolment will close: June 2019

Trial phase 

Phase 1
Phase 2
Phase 3
Phase 4